Suppr超能文献

中药复方联合传统西药治疗骨质疏松协同作用的Meta分析

Meta-analysis of the synergistic effect of traditional Chinese medicine compounds combined with conventional Western medicine in the treatment of osteoporosis.

作者信息

Jin Huan, Huang Cai, Zhang Yan, Dong Ying, Xiong Qi, Wang Di, He Ziyi, Shen Lin, Ma Chen, Wang Zixian, Zeng Lingfeng, Shuai Bo

机构信息

Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

College of Sports Medicine, Wuhan Sports University, Wuhan, China.

出版信息

Front Endocrinol (Lausanne). 2025 May 29;16:1606753. doi: 10.3389/fendo.2025.1606753. eCollection 2025.

Abstract

BACKGROUND

As a global public health problem, osteoporosis (OP) urgently requires better treatment strategies. This study systematically evaluated the synergistic effect of traditional Chinese medicine (TCM) compounds combined with conventional Western medicine (such as bisphosphonates and calcium) compared to Western medicine alone in the treatment of OP through a meta-analysis.

METHODS

Based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses and the Measurement Tool for Systematic Review Assessment guidelines, databases such as PubMed and Embase were systematically searched (as of March 2025), and 13 randomized controlled trials (RCTs), involving a total of 2,403 patients, were included.

RESULTS

The integrated Chinese and Western medicine group showed significantly higher lumbar and femoral neck Bone mineral density (BMD) growth rates than the control group, alongside reduced pain visual analogue scale (VAS) scores. Mechanistically, the combination therapy synergistically modulated bone turnover markers: the bone resorption marker type I collagen C-terminal peptide (CTX-1) decreased (MD = -1.33, P = 0.05), the bone formation marker osteocalcin (OC) increased (MD = 15.56, P < 0.0001), suggesting dual regulation of osteoclast inhibition (e.g., via Receptor Activator of Nuclear Factor-κ B Ligand (RANKL) suppression) and osteoblast activation (e.g., via Wnt/β-catenin signaling). Notably, Procollagen I N-Terminal Propeptide (P1NP) levels remained unchanged (P = 0.63), indicating differential targeting of bone formation pathways. Subgroup analyses revealed stronger BMD improvements with short-term interventions (3-6 months), potentially linked to early osteoclast activity suppression by TCM compounds (e.g., icariin in Xianling Gubao), whereas diminished long-term efficacy (12-24 months) may reflect adaptive bone remodeling plateaus. Fracture incidence and safety profiles did not differ between groups.

CONCLUSION

Current evidence supports the potential of integrated TCM and Western medicine therapy in improving BMD and reducing pain. However, its clinical application requires further validation through large-scale, long-term, and standardized RCTs. Future research should focus on standardizing TCM compound ingredients, exploring the mechanisms of combined therapies, and conducting long-term safety assessments.

SYSTEMATIC REVIEW REGISTRATION

https://doi.org/10.17605/OSF.IO/G73SH.

摘要

背景

作为一个全球性的公共卫生问题,骨质疏松症(OP)迫切需要更好的治疗策略。本研究通过荟萃分析系统评价了中药复方联合传统西药(如双膦酸盐和钙剂)与单纯西药相比在治疗OP中的协同作用。

方法

根据系统评价和荟萃分析的首选报告项目以及系统评价评估指南的测量工具,对PubMed和Embase等数据库进行系统检索(截至2025年3月),纳入13项随机对照试验(RCT),共涉及2403例患者。

结果

中西医结合组腰椎和股骨颈骨密度(BMD)增长率显著高于对照组,疼痛视觉模拟量表(VAS)评分降低。机制上,联合治疗协同调节骨转换标志物:骨吸收标志物I型胶原C端肽(CTX-1)降低(MD=-1.33,P=0.05),骨形成标志物骨钙素(OC)升高(MD=15.56,P<0.0001),提示对破骨细胞抑制(如通过核因子κB受体激活剂配体(RANKL)抑制)和成骨细胞激活(如通过Wnt/β-连环蛋白信号通路)的双重调节。值得注意的是,I型前胶原N端前肽(P1NP)水平保持不变(P=0.63),表明对骨形成途径的靶向作用不同。亚组分析显示,短期干预(3-6个月)对BMD的改善更强,这可能与中药复方(如仙灵骨葆中的淫羊藿苷)早期抑制破骨细胞活性有关,而长期疗效(12-24个月)减弱可能反映了适应性骨重塑平台。两组之间骨折发生率和安全性概况无差异。

结论

目前的证据支持中西医结合疗法在改善BMD和减轻疼痛方面的潜力。然而,其临床应用需要通过大规模、长期和标准化的RCT进一步验证。未来的研究应集中在规范中药复方成分、探索联合疗法的机制以及进行长期安全性评估。

系统评价注册

https://doi.org/10.17605/OSF.IO/G73SH。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f529/12158694/261593bfe839/fendo-16-1606753-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验